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Abstract
Introduction Radiotherapy (RT) is considered a standard
treatment option after surgery for breast cancer. Letrozole, an
aromatase inhibitor, is being evaluated in the adjuvant setting.
We determined the effects of the combination of RT and
letrozole in the aromatase-expressing breast tumour cell line
MCF-7CA, stably transfected with the CYP19 gene.
Methods Irradiations were performed using a cobalt-60 source
with doses ranging from 0 to 4 Gy. Cells were incubated with
androstenedione in the presence or absence of letrozole.
Effects of treatment were evaluated using clonogenic assays,
tetrazolium salt colorimetric (MTT) assays, and cell number
determinations. Cell-cycle analyses were conducted using flow
cytometry.
Results The survival fraction at 2 Gy was 0.66 for RT alone and
was 0.44 for RT plus letrozole (P = 0.02). Growth of MCF-7CA
cells as measured by the cell number 6 days after radiotherapy
(2 and 4 Gy) was decreased by 76% in those cells treated
additionally with letrozole (0.7 µM) compared with those
receiving radiotherapy alone (P  = 0.009). Growth inhibition,
assessed either by cell number (P = 0.009) or by the MTT assay
(P = 0.02), was increased after 12 days of the combination
treatment. Compared with radiation alone, the combination of
radiation and letrozole produced a significant decrease in
radiation-induced G2 phase arrest and a decrease of cells in the
S phase, with cell redistribution in the G1 phase.
Conclusions These radiobiological results may form the basis
for concurrent use of letrozole and radiation as postsurgical
adjuvant therapy for breast cancer.
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Introduction
The aromatase inhibitor letrozole has been shown to be
superior to tamoxifen (TAM) in the first-line treatment of
metastatic breast cancer [1,2]. A randomized clinical trial
comparing these two drugs in the adjuvant setting is cur-
rently ongoing, and should soon provide insight into the rel-
ative efficacy of letrozole and TAM. Another adjuvant trial,
the MA.17 study, evaluated patients from the National Can-
cer Institute of Canada Clinical Trials Group who were dis-
ease-free after initially being treated with 5 years of TAM
and then being randomized to receive either 5 years of pla-
cebo or 5 years of letrozole treatment. As compared with
placebo, letrozole therapy after the completion of TAM
treatment significantly improved disease-free survival [3].
Postoperative radiotherapy (RT) decreases the risk of loco-
regional recurrence. RT is also associated with improved
survival in high-risk premenopausal and postmenopausal
women with breast cancer given either adjuvant chemo-
therapy [4] or TAM [5], respectively. Whether letrozole sen-
sitizes breast cancer cells to RT has not been determined.
The present study has examined this question in vitro, using
DCC = dextran-coated charcoal; DMEM = Dulbecco's modified Eagle's medium; FCS = foetal calf serum; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-
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a human breast cancer cell line stably transfected with the
human aromatase gene. We present herein the capacity of
letrozole to sensitize these cells to RT using clonogenic,
MTT, and cell-count assays. Cell-cycle analyses showed a
G1 phase arrest and a decrease of the S phase with letro-
zole as compared with control cells. Moreover, compared
with RT alone, combined RT and letrozole produced a sig-
nificant decrease in radiation-induced G2 phase arrest and
in the number of cells in the S phase, with cell redistribution
in the G1 phase.
Materials and methods
Cell line, culture, and letrozole
MCF-7 human breast cancer cells stably transfected with
the human aromatase/CYP19 gene (MCF-7CA) were
kindly provided by Dr S Chen (City of Hope, Duarte, CA,
USA [6]). These cells were maintained in DMEM/NUT MIX
F-12 containing 10% heat-inactivated FCS (Gibco Labora-
tories, Cergy Pontoise, France), 500 µg/ml geneticin
(G418), 300 µg/ml glutamine, 0.25 µg/ml fungizone, 100
µg/ml streptomycin, and 100 units/ml penicillin G. The two
cell lines, MCF-7 wild type and MCF-7CA, were adherent
and grew as monolayers at 37°C in a humidified 5% CO2
incubator. The cells were harvested with 0.5 g/l trypsin
(Gibco Laboratories) and 0.2 g/l EDTA (Gibco Laborato-
ries) for 3 min. Cultures were checked for the absence of
mycoplasma every month.
Steroids were removed from the FCS by two treatments
with dextran-coated charcoal (DCC) [7]. Cells were cul-
tured as monolayers in 60-mm Petri dishes with phenol-
red-free medium and DCC FCS.
Letrozole used in the study was synthesized in the labora-
tories of Novartis Pharma AG (Basel, Switzerland). In all
experiments, letrozole was added to cultures that were
nonconfluent at concentrations of 7 nM–0.7 µM in 10 µl
ethanol 6 days before RT.
Aromatase tritiated water assay
Aromatase activity was determined using the 3H2O release
method reported by Zhou and colleagues [6], based on the
procedure described by Thompson and Siiteri [8]. Cells
were maintained for 5 days in 10% FCS phenol-red-free
medium and then seeded at 700,000 cells per well in six-
well dishes with fresh DCC-treated medium. Three days
later, culture plates were washed twice with PBS. One mil-
litre of serum-free medium containing 40 nM 1β-3H(N)-
androst-4-ene-3,17-dione (NET-926; NEN PerkinElmer
Life Sciences, Inc., Courtaboeuf, France) as substrate
(specific activity, 25.9 Ci/mmol) with or without 100 nM
letrozole was then added to each well. After 6 hours of
incubation at 37°C, the reaction mixture was removed and
extracted with two volumes of chloroform to terminate the
reaction and to extract unused substrate and steroids. After
5 min centrifugation at 100 × g, the aqueous phase was
then treated with an equal volume of 5% charcoal suspen-
sion to eliminate residual steroids. After 5 min centrifuga-
tion at 15,000 × g, radioactivity was assessed by liquid
scintillation counting. The protein concentration was deter-
mined by the Bradford method [9] after cell extraction with
Reporter Lysis 5X Buffer according to the manufacturer's
instructions (PROMEGA Corp., Lyon, France). Aromatase
activity was then calculated from the disintegrations per
minute as picomoles of oestrogen produced by milligrams
of protein per hour
Radiation modalities
Cells were plated in 10 ml DCC and phenol-red-free
medium (to ensure homogeneous energy deposition within
each dish using 60-mm Petri dishes) and irradiated with a
cobalt-60 source (γ irradiation, ELITE 100; Theratronics,
Ottawa, ON, Canada) in the Radiation Department. The
radiation was delivered as a single dose ranging from 0 to
4 Gy in an 11 cm × 11 cm field size at a dose rate of 0.5
Gy/min. A 3-cm polystyrene block was used under the Petri
dishes during each irradiation to allow homogeneous back-
scattering γ-rays. The source-half-depth distance was ini-
tially calculated to obtain a constant dose rate of 0.5 Gy/
min, and was adapted monthly to the cobalt-60 source radi-
oactivity decay. Control cells were removed from the incu-
bator and were placed for the same period of time under
the cobalt-60 source but without RT. In the combined treat-
ment modality studies, letrozole was added 6 days prior to
RT.
Cytotoxicity assays
Cultures were trypsinized and washed, and cells were
plated in quintuplicate at a density of 100 cells per 60-mm
Petri dish after dilution. Letrozole was added at concentra-
tions ranging from 7 nM to 0.7 µM 24 hours after the cells
were plated to allow for cell attachment. Cells were incu-
bated at 37°C in a humidified chamber containing 5% CO2
for 12 days. The colonies were then fixed with a 1:3 (v/v)
acetic acid methanol solution and were stained with 10%
Giemsa (Sigma Chemical Co., St Louis, MO, USA); colo-
nies of greater than 50 cells were scored. The plating effi-
ciency was calculated with and without letrozole.
The cytotoxicity of RT against asynchronous, exponentially
growing cells was also determined from colony formation
assays. Before irradiation, the cell density was determined
using appropriate dilutions (100, 100, 200, 300, and 400
cells for 0, 1, 2, 3, and 4 Gy, respectively), and cells were
plated onto five replicate 60-mm Petri dishes. Cells were
irradiated as already described 24 hours after plating to
allow for cell attachment before the administration of RT.
The letrozole-containing medium was given at a concentra-
tion of 0.7 µM 6 days before RT. Cultures were irradiated
with the drug present in the medium, and were immediatelyAvailable online http://breast-cancer-research.com/content/7/1/R156
R158
returned to the incubator after irradiation. Colonies were
counted after 12 days.
Experimentally derived data points are the mean of five
experiments. The dose–response curves were fitted to a
four-parameter model, where the response R varies with
the dose D according to the equation: R = a/[1 + (D/b)c] +
R∞, where a is the difference between the maximum and
minimum response, b is the concentration of drug needed
to obtain 50% of the maximal effect, c is a slope factor, and
R∞ is the maximal effect. The multitarget model survival
curves were fitted to the data using a least-squares regres-
sion to the linear-quadratic model: S = S0 exp(-αD1 - βD1
2),
where D1 is the radiation dose, S is the surviving fraction,
and S0 is a normalizing parameter.
MTT and cell number assays
The antiproliferative effect of letrozole with or without RT on
the MCF-7CA cell line was evaluated using the MTT assay
as described by Mosmann [10]. Briefly, exponentially grow-
ing cells were seeded into 96-well plates and were incu-
bated in medium containing letrozole from 7 nM to 0.7 µM
for 48 hours at 37°C. Duplicate plates containing six repli-
cate wells/assay condition were seeded in 0.1 ml medium
at densities of 5000, 15,000, and 35,000 cells per well,
and were then treated with letrozole alone, with RT (2 Gy)
± letrozole (0.7 µM), and with RT (4 Gy) ± letrozole (0.7
µM), respectively. Twelve days after letrozole ± RT (2 or 4
Gy) treatment, the viability of the cells was analysed using
the tetrazolium salt (Sigma) MTT colorimetric assay. Briefly,
50 µl of a 0.5% MTT solution was added to each well, fol-
lowed by incubation for 4 hours at 37°C to allow MTT
metabolization. The crystals formed were dissolved by add-
ing 100 µl/well isopropylic alcohol, 1 N HCl. The absorb-
ance at 540 nm was measured on a Microtiter® Plate
Reader MRX (Dynatech Laboratories, Chantilly, VA, USA).
The results were expressed with respect to control values
(cells without any treatment).
The antiproliferative effect of letrozole ± RT on the MCF-
7CA cell line was also evaluated using a cell-count assay.
MCF-7CA cells were allowed to grow for 24 hours, at
which time letrozole was added at a concentration of 0.7
µM. RT (2 and 4 Gy) was delivered to those cells receiving
the combination treatment 6 days after the addition of letro-
zole to the medium. Cells were counted every 6 days (days
6, 12, and 18) over an 18-day period after removing the
cells from the plates with 0.5 g/l trypsin.
Flow cytometry
Cells were plated in 60-mm Petri dishes at a density of 2 ×
106 cells/dish. Treatment consisted of letrozole (0.7 µM)
alone, RT (2 and 4 Gy) alone, or letrozole (0.7 µM) plus RT
(2 and 4 Gy). Cells were collected 15 days after plating,
and were processed for cell-cycle analysis. Cells were har-
vested by trypsinization, were washed with PBS, and then
1 × 106 cells/dish of treated cells were fixed in 70% etha-
nol for 2 min. After removal of ethanol by centrifugation,
cells were then stained with a solution containing 40 µg/ml
propidium iodide (Sigma) and 0.1 mg/ml RNase A (Roche,
Indianapolis, IN, USA). Stained nuclei were analysed for
DNA-PI fluorescence using a Becton-Dickinson FACScan
flow cytometer (Mountain View, CA, USA). Resulting DNA
distributions were analysed using the CellQUEST software
(Becton Dickinson) for the proportion of cells in the sub-G0
phase, the G1 phase, the S phase, and the G2–M phase of
the cell cycle.
In a second series of experiments, cells were treated with
letrozole (0.7 µM) alone and were then cultured for 21
days. Cells were stained at different time points up to 21
days and were analysed for DNA content on a FACScan as
already described.
Statistical analysis
The nonparametric Wilcoxon signed-rank test was used to
compare the surviving fraction for each dose between the
two groups (RT alone and RT plus letrozole). All experi-
ments were performed three times and the results are
expressed as the mean ± standard error. All statistical tests
were two-sided with an alpha level of 0.05. Data were ana-
lysed using the STATA 7.0 software (Stata Corporation,
College Station, TX, USA).
Results
Letrozole inhibits MCF-7CA aromatase activity
The aromatase activity was induced by the androgenic sub-
strate ∆4 androstenedione at a 40 nM concentration. The
effects of letrozole on aromatase activity in cultured breast
cancer cells are shown in Fig. 1. In the MCF-7CA trans-
fected cell line, letrozole (100 nM) markedly inhibited aro-
matase activity.
Letrozole inhibits MCF-7CA proliferation
The cytotoxic effects of several concentrations of letrozole
(7 nM–0.7 µM) on asynchronous, exponentially growing
MCF-7CA cells were determined by cell-count assay.
Letrozole at a concentration of 7 nM did not inhibit the
growth of MCF-7CA cells during 18 days of incubation,
whereas 0.7 µM resulted in about 50 ± 10% inhibition after
6, 12, and 18 days of incubation (Fig. 2). No effect of letro-
zole was seen on MCF-7 wild-type cells.
Letrozole enhances radiosensitivity
Cell survival following RT in aerated medium fits a linear
quadratic model, as described in Materials and methods.
Figure 3 depicts normalized results from clonogenic exper-
iments. The survival fraction at 2 Gy was 0.66 ± 0.05, and
the D0 value (dose of radiation producing a 37% survival
rate) was 3.2 Gy when irradiation was used alone.Breast Cancer Research    Vol 7 No 1    Azria et al.
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Letrozole added 6 days before RT led to a greater
decrease of the surviving fractions as compared with those
obtained when letrozole was added 3 days before RT,
when letrozole was added 3 days after RT or when RT was
delivered alone. Treatment at 6 days before RT led to a sur-
vival fraction at 2 Gy and a D0 value of 0.46 ± 0.05 and 2.2
Gy, respectively. The survival fraction at 2 Gy was thus
nearly 30% (±4%) lower for the combination treatment,
with a significant test result (P = 0.02). When the data
were analysed according to the linear quadratic model, the
α and β components were, respectively, nearly 0/Gy and
0.098 ± 0.0038/Gy2 without letrozole, and were nearly 0/
Gy and 0.154 ± 0.014/Gy2 for the combination treatment.
These data indicate that treatment with letrozole results in
a steeper decline in cell survival due both to a higher initial
slope of the dose–response curve and to a major decrease
of the quadratic parameter. These results thus show possi-
ble additive effects for the combined treatment.
Growth of MCF-7CA cells measured by MTT assay was
inhibited to a 40 ± 6% greater extent with letrozole plus 2
Gy RT, and to a 76 ± 3% greater extent with letrozole plus
4 Gy RT, compared with radiation alone (P = 0.02) (Fig. 4).
Growth of MCF-7CA cells measured by cell-count assay
was determined for an 18-day period after initial treatment.
It was inhibited to a 76 ± 2% greater extent after 12 days,
and to an 85 ± 4% greater extent after 18 days, for letro-
zole treatment plus 2 or 4 Gy RT compared with RT alone
(P = 0.009) (Fig. 5).
Figure 1
Aromatase activity in MCF-7 wild-type (wt) and MCF-7CA transfected  cell lines Aromatase activity in MCF-7 wild-type (wt) and MCF-7CA transfected 
cell lines. Aromatase activity was measured by the tritiated water assay. 
Treatment with letrozole inhibited the 40 nM 1β-3H-androstenedione 
substrate conversion. Open bars, filled bars, and grey bars represent 
background radioactivity, aromatase activity without treatment, and aro-
matase activity after treatment with letrozole (100 nM), respectively.
Figure 2
Growth inhibition with letrozole alone Growth inhibition with letrozole alone. (a) Seven nanomolar letrozole 
did not inhibit the growth of MCF-7CA cells during 18 days of incuba-
tion, whereas (b) 0.7 µM letrozole resulted in about 50% inhibition after 
6, 12, and 18 days of incubation. Results are from cell-count assays.
Figure 3
Potentiation of radiation-induced growth inhibition by letrozole meas- ured by clonogenic assay Potentiation of radiation-induced growth inhibition by letrozole meas-
ured by clonogenic assay. With radiation alone the MCF-7CA cell sur-
vival fraction decreased in a dose-dependent manner, which was 
significantly potentiated by the addition of 0.7 µM letrozole. For 2 Gy 
radiation, the surviving fraction was 0.66 with radiation alone and was 
0.46 with the addition of letrozole (P = 0.02). For 3 Gy radiation, the 
corresponding surviving fractions were 0.4 and 0.18, respectively (P = 
0.02).Available online http://breast-cancer-research.com/content/7/1/R156
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Letrozole induces G1 cell-cycle arrest
The effect of letrozole treatment on cell-cycle phase distri-
bution in the MCF-7CA cell line was evaluated using flow
cytometry (Fig. 6). Treatment with 0.7 µM letrozole for 6
days induced accumulation of cells in the G1 phase (77.5
± 1.5%), with a significant decrease in the percentage of
cells in the S phase (9.0 ± 1%) relative to controls (20.4 ±
0.7%). No cells with subdiploid DNA content were
observed, demonstrating that letrozole does not induce
apoptosis in these cell lines.
After 6 days of treatment, cells were further cultured for 21
days in the presence of letrozole. A G1 cell-cycle arrest
(nearly 70%) was observed at days 12 and 21. One day
after RT alone, we observed a cell-cycle arrest in the G2
phase (32 ± 0.3%) with a decrease in the percentage of
cells in the G0/G1 phase and the S phase as compared
with the control (59 ± 0.8% versus 63 ± 1.2%, and 9 ±
0.4% versus 20.4 ± 0.7%, respectively). When letrozole
was added 6 days before RT, the radiation-induced G2/M
phase arrest decreased compared with RT alone (21 ±
0.6% versus 32 ± 0.3%, respectively), with a letrozole-
induced G0/G1 phase blockade and a very low proportion
of cells in the S phase.
Discussion
TAM is the most widely used endocrine agent for the adju-
vant therapy of early breast cancer in postmenopausal
women [11]. TAM use nevertheless remains limited, most
notably by its recognized pharmacological properties and
side effects. For instance, TAM has been associated with
an increased risk of both thromboembolic events and
endometrial changes, including endometrial cancer
[12,13]. It is possible, therefore, that other endocrine drugs
may provide at least equivalent, if not superior, efficacy
together with improved tolerability in patients with early dis-
ease. In this context, the third-generation aromatase
inhibitors are now under investigation, and the initial results
may substantially change our current clinical practice pat-
terns [3,14,15].
The efficacy of breast-conserving surgery with axillary dis-
section and breast radiation has been known for a long time
[16]. Overgaard and colleagues more recently demon-
strated that postoperative radiotherapy decreases the risk
of locoregional recurrence, and that it is associated with
improved survival in high-risk patients with breast cancer
given either adjuvant chemotherapy (in premenopausal
women) [4] or tamoxifen (in postmenopausal women) [5].
In the present study, we wanted to evaluate in vitro the
effects of the combination of ionizing radiation and
letrozole, one of the third-generation aromatase inhibitors.
To our knowledge, our results demonstrate for the first time
that letrozole could act as a potent radiosensitizer. A signif-
icant effect was observed in all three assays used in our
experiments (clonogenic, MTT, and cell count). The effects
of associating other hormonotherapies, such as TAM, with
radiotherapy have been rarely described and remain poorly
defined. TAM appears to exert its cytostatic activity at least
Figure 4
Potentiation of radiation-induced growth inhibition by letrozole meas- ured by the MTT assay Potentiation of radiation-induced growth inhibition by letrozole meas-
ured by the MTT assay. Growth of MCF-7CA cells, measured 6 days 
after treatment, was inhibited to a 40% greater extent with letrozole 
plus 2 Gy radiation, and to a 76% greater extent with letrozole plus 4 
Gy radiation, compared with radiation alone.
Figure 5
Potentiation of radiation-induced growth inhibition by letrozole meas- ured by cell-count assay Potentiation of radiation-induced growth inhibition by letrozole meas-
ured by cell-count assay. Growth of MCF-7CA cells, measured for 18 
days after treatment, was inhibited to a 76% greater extent with letro-
zole plus 4 Gy radiation after 12 days, and to an 85% greater extent 
after 18 days, compared with radiation alone. Solid lines, ■  and ◆  rep-
resent radiation alone at 2 Gy and 4 Gy, respectively; dotted lines, ■  
and ◆  represent combination of radiation plus letrozole (0.7 µM) at 2 
Gy and 4 Gy, respectively.Breast Cancer Research    Vol 7 No 1    Azria et al.
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partly through competitive inhibition of oestrogen binding
at the oestrogen receptor, resulting in segregation of cells
into the G0/G1 phase of the cell cycle [17]. Because rela-
tively less radiosensitivity was observed in the early G1
phase [18], a hypothetical concern was raised in several
studies that the use of TAM during RT might result in the
radioprotection of tumour clonogens of both hormonally
responsive and unresponsive breast carcinoma cells at
dose levels typically used in clinical practice [19]. In these
studies, however, cell cultures were grown in a medium
containing phenol red and foetal bovine serum, two
sources of exogenous estrogenic compounds [20-23].
This fact complicates the interpretation of the resultant radi-
ation survival curves [24]. In contrast to these reports, no
significant differences were observed in radiosensitivity for
oestradiol-stimulated or 4-hydroxytamoxifen-inhibited cul-
tures plated into growth-stimulating conditions immediately
after irradiation or following an additional 24 hours in oes-
trogen-free conditions [25]. Clearly, under defined hormo-
nal conditions [26], no protective effect of the active TAM
metabolite 4-hydroxytamoxifen was observed [25].
Our data suggest that letrozole inhibits cell proliferation by
invoking a transition delay or by blocking in the G1 phase of
Figure 6
Effect of letrozole (0.7 µM) or/and radiotherapy (RT) on MCF-7CA cell-cycle progression Effect of letrozole (0.7 µM) or/and radiotherapy (RT) on MCF-7CA cell-cycle progression. (a) Control cells were compared with (b) MCF-7CA cells 
harvested after exposure to letrozole. In the case of RT treatment, cells were harvested after RT (c) without or (d) with letrozole. Cells were fixed and 
stained with propidium iodide for flow cytometry analysis as described in Materials and methods. Percentages of the G0/G1 phase, the S phase, and 
the G2/M phase were determined by CellQUEST analysis software on the basis of DNA content of the histogram. Data represent mean values of 
duplicate samples. Similar results were obtained in replicate experiments.Available online http://breast-cancer-research.com/content/7/1/R156
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the cell cycle. This delay may require more than one com-
plete passage of some cells through the cell cycle, since
cell numbers more than doubled before the plateau growth
phase was reached. In addition, two to three generation
times were required for maximal accumulation of cells in the
G1 phase. We therefore added letrozole 6 days before RT.
Under defined hormonal conditions, we found more than an
additive effect [27] using the combination of letrozole and
RT at each dose tested. This result was reinforced by the
poor effect of letrozole used alone at high concentration (7
µM) and tested in all combination treatments. Isobologram
analyses are planned to confirm the existence of either an
additive effect or a supra-additive effect for the association
of these two treatment modalities in a future study, as pro-
posed by Steel [28].
A small percentage of cells was insensitive to letrozole, and
remained in the proliferative fraction (9% in the S phase).
The mechanism of unresponsiveness of these cells to letro-
zole will require further study. As shown with anti-oestro-
gens [17], these data are consistent with the hypothesis
that aromatase inhibitors such as letrozole induce regres-
sion of breast cancer in vivo by simply blocking progres-
sion of cells through the cell cycle rather than by a direct
cytotoxic effect. With cell replication inhibited, tumours
might then regress because of ongoing cell shedding or
death, or because of interaction with normal host defences.
In the RT–letrozole combination treatment, we observed a
50% decrease of MCF-7CA cells arrested in the G2 phase
as compared with RT alone, a proportional redistribution in
the G1 phase, and an interrupted synthesis phase for an 18-
day period. This cell-cycle redistribution phenomenon may
also explain the decrease in the surviving fraction in the
combination treatment presented in the present study (Fig.
3).
In addition, associating irradiation and letrozole may modify
the cytosolic oestrogen and progesterone receptor content
in breast cancer cells, which might explain the observed
changes in these cells' radiation sensitivity during hormonal
treatment, as published with TAM [29].
These results may have important clinical implications for
the treatment of breast cancer. Since the adjuvant use of
aromatase inhibitors is still an emerging treatment option
[3,14,15], the most effective time at which to commence
the use of these drugs after surgery is not yet known. Also,
if letrozole is simply placing hormone-responsive breast
cancer cells into a 'resting' phase of the cell cycle (G0–G1
phase), then treatment of patients after surgery for primary
breast cancer with adjuvant letrozole may have to be con-
tinued at least long enough for host defences or normal cell
attrition to eradicate residual tumour cells. Premature dis-
continuation of therapy might lead to tumour regrowth.
Finally, where letrozole is used concurrently with RT, we
recommend starting letrozole at least 3 weeks before the
start of RT in an attempt to obtain an optimal effect, consist-
ent with the biological rationale described earlier. Further-
more, and in so far as the preclinical data with breast
cancer cells can be extrapolated to the clinical situation, a
radiosensitizing effect may be observed in the healthy
breast. Nevertheless, Miller and colleagues showed a rising
aromatase activity level in adipose tissue obtained from
patients with breast cancer and within the quadrant
involved with the tumour [30-32].
Conclusions
These results are the first preclinical findings demonstrat-
ing the radiosensitization effect of letrozole, and thus may
provide a basis for the use of combined letrozole and radi-
ation for the adjuvant therapy in breast cancer patients.
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